Novo Nordisk's Wegovy pill sales beat Wall Street forecasts in third quarter
The oral obesity drug's performance widens Novo's early edge over Eli Lilly in the pill segment of the weight loss market.
Read at Biopharmadive โFull coverage ยท 12 outlets
- Biopharmadive ยท lead
- BioPharma DiveNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
- QuartzNovo Nordisk raises forecast as pill sales beat Q3 2026 estimates
- ReutersNovo hikes outlook again as it speeds up Wegovy pill rollout
- Yahoo FinanceNovo Nordisk CEO: Wegovy pill 'exceeded our expectations'
- BigGo FinanceNovo Nordisk Lifts 2026 Guidance as Wegovy Pill Sales Top Forecasts
- CNBCNovo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
- FirstWord PharmaNovo's upbeat forecast can't overcome disappointments from oral Wegovy, CagriSema
- Investor's Business DailyNovo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up
- Manufacturing ChemistNovo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings
- TipRanksNovo Reports Q3 Beat, Raises 2026 Sales Forecast on Obesity Demand; NVO Stock Jumps 5%
- YahooNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts